No information is available about crizanlizumab during breastfeeding. Because crizanlizumab is a large protein molecule with a molecular weight of about 146,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] Until more data become available, crizanlizumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.
关于哺乳期使用crizanlizumab的信息尚无定论。由于crizanlizumab是一种分子量约为146,000 Da的大分子蛋白质，乳汁中的含量可能非常低。它也可能在婴儿胃肠道中被部分破坏，婴儿的吸收可能微乎其微。产后至少等待2周再恢复治疗可能会将药物转移至婴儿的情况降至最低。[1] 在获得更多数据之前，哺乳期使用crizanlizumab时应谨慎，尤其是在喂养新生儿或早产儿期间。
